Zai Lab (ZLAB) to Release Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Zai Lab Trading Down 1.6%

Shares of NASDAQ:ZLAB opened at $19.72 on Tuesday. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -10.11 and a beta of 0.88. Zai Lab has a 12 month low of $15.96 and a 12 month high of $44.34. The company has a 50-day moving average price of $18.28 and a 200-day moving average price of $24.60.

Insider Activity at Zai Lab

In other news, insider Rafael Amado sold 10,787 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total value of $188,017.41. Following the sale, the insider directly owned 52,391 shares of the company’s stock, valued at $913,175.13. This represents a 17.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.96% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada raised its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. Institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group assumed coverage on Zai Lab in a research report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. JPMorgan Chase & Co. dropped their target price on shares of Zai Lab from $46.00 to $39.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Finally, Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.59.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.